Published in J Clin Endocrinol Metab on June 03, 2013
Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers (Pasireotide) | NCT01128192
Treatment of Cushing's Disease With R-roscovitine | NCT02160730
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab (2014) 1.29
Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol (2015) 1.02
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med (2015) 0.90
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord (2016) 0.86
Pasireotide for the Medical Management of Feline Hypersomatotropism. J Vet Intern Med (2015) 0.85
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. Pituitary (2015) 0.85
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine (2016) 0.84
Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci (2013) 0.83
New therapeutic agents for acromegaly. Nat Rev Endocrinol (2015) 0.81
Recent advances in the management of acromegaly. F1000Res (2015) 0.79
Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary (2016) 0.77
Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther (2016) 0.77
Recent advances in the medical treatment of Cushing's disease. F1000Prime Rep (2014) 0.76
Successful Medical Treatment of Adult Nesidioblastosis With Pasireotide over 3 Years: A Case Report. Medicine (Baltimore) (2016) 0.75
Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. Endocrinology (2016) 0.75
Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism. J Vet Intern Med (2017) 0.75
Medical Therapy with Pasireotide in Recurrent Cushing's Disease: Experience of Patients Treated for At Least 1 Year at a Single Center. Front Endocrinol (Lausanne) (2017) 0.75
Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine (2017) 0.75
Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia. Endocrinol Diabetes Metab Case Rep (2017) 0.75
Update on medical treatment for Cushing's disease. Clin Diabetes Endocrinol (2016) 0.75
Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats. Endocrine (2017) 0.75
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2010) 4.23
Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care (2003) 2.36
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol (2009) 2.21
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab (2007) 2.02
A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res (2006) 1.94
Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes (2009) 1.83
Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. Arch Gen Psychiatry (2005) 1.75
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab (2007) 1.70
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril (2007) 1.63
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes (2003) 1.62
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. J Clin Psychiatry (2012) 1.48
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 1.44
Pioglitazone: side effect and safety profile. Expert Opin Drug Saf (2010) 1.37
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest (2011) 1.33
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab (2007) 1.17
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes (2002) 1.15
Physician and staff perceptions of barriers to colorectal cancer screening in Appalachian Kentucky. Cancer Control (2007) 1.13
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab (2008) 1.13
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol (2007) 1.10
Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci (2011) 1.08
Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab (2005) 1.07
Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome. J Clin Psychopharmacol (2009) 1.07
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet (2007) 1.07
Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes (2002) 1.06
Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res (2005) 1.04
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care (2002) 1.03
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res (2008) 1.03
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab (2008) 1.01
Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte (2013) 1.01
Evolution of exenatide as a diabetes therapeutic. Curr Diabetes Rev (2013) 1.00
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol (2007) 0.99
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol (2004) 0.98
Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res (2010) 0.98
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab (2006) 0.97
In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am J Physiol Endocrinol Metab (2010) 0.95
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab (2003) 0.94
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol (2006) 0.93
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet (2007) 0.93
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism (2003) 0.92
Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS One (2007) 0.92
Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol (2014) 0.91
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab (2009) 0.90
Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab (2008) 0.89
Enhanced insulin signaling via Shc in human breast cancer. Metabolism (2003) 0.89
Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care (2002) 0.88
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab (2003) 0.88
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol (2007) 0.87
Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance. Am J Physiol Endocrinol Metab (2014) 0.85
Discontinuation of quetiapine from an NIMH-funded trial due to serious adverse events. Am J Psychiatry (2009) 0.85
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. Pituitary (2015) 0.85
Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab (2004) 0.85
Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J Clin Hypertens (Greenwich) (2010) 0.84
Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. J Nutr Biochem (2013) 0.83
Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care (2003) 0.83
Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications (2006) 0.83
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin (2007) 0.82
Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels. Surg Obes Relat Dis (2008) 0.81
Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients. J Clin Psychiatry (2010) 0.81
Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa. Clin Sci (Lond) (2013) 0.81
Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J Clin Pharmacol Ther (2013) 0.81
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab (2012) 0.80
Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Curr Med Res Opin (2009) 0.80
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol (2007) 0.80
The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. Curr Med Res Opin (2004) 0.80
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin (2007) 0.79
Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor I. J Clin Endocrinol Metab (2005) 0.79
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab (2015) 0.79
Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects. Metabolism (2002) 0.78
Efforts to improve subsequent treatment of cardiovascular risk factors in older patients with diabetes hospitalized for a cardiac event. Am J Manag Care (2005) 0.78
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin (2008) 0.77
Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single‐Center, Phase I, Randomized, Four‐Way Crossover Study. J Clin Pharmacol (2014) 0.77
Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol (2003) 0.77
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. Br J Clin Pharmacol (2010) 0.77
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin (2009) 0.77
Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes. J Clin Pharmacol (2007) 0.75
Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids. Endocrine (2008) 0.75
Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. Eur J Clin Pharmacol (2004) 0.75